Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Terminated 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Recurrence 36Colorectal Neoplasms 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 27Pancreatic Neoplasms 25Melanoma 25Lymphoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Urinary Bladder Neoplasms 17Leukemia 17Head and Neck Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

spartalizumab 1balstilimab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Hemangiosarcoma × Clear all
NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡